1
LETTER TO THE EDITOR Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients Satoru Takeuchi & Kojiro Wada & Kimihiro Nagatani & Naoki Otani & Hideo Osada & Hiroshi Nawashiro Received: 12 August 2011 /Accepted: 27 September 2011 /Published online: 25 October 2011 # Springer-Verlag 2011 Vergouwen et al. reported that intravenous tissue plasmin- ogen activator (IV tPA) treatment was not associated with an increased risk of secondary intracerebral hemorrhage or gastrointestinal hemorrhage in patients with acute ischemic stroke taking warfarin with an international normalized ratio (INR) <1.7 [6]. These results mean that IV tPA treatment should not be discouraged in patients taking warfarin with INR <1.7. Recently, dabigatran, a new oral anticoagulant, was approved by the FDA. In the Randomized Evaluation of Long-Term Anticoagulant Therapy trial, dabigatran was shown to be as effective as warfarin in prevention of systemic embolism and future stroke, with lower risk of major hemorrhage [2]. Additionally, dabigatran does not need monitoring (differently from warfarin). Therefore, the number of dabigatran-treated patients presenting with ischemic stroke may increase in the future. However, there is no guideline whether dabigatran-treated patients presenting with ischemic stroke can be considered eligible for IV tPA treatment or not. Only two case reports demonstrated the safety of IV tPA treatment for acute ischemic stroke in dabigatran-treated patient [3, 5]. On the other hand, Ammollo et al. reported that dabigatran enhanced the susceptibility of plasma clots to tPA-induced lysis in in vitro study [1]. Based on Ammollos results, we can hypothesize that dabigatran may also enhance the bleeding risk caused by tPA. Although we recognize the lack of data on IV tPA treatment for acute ischemic stroke in dabigatran-treated patients, we need provisional guidelines of the topic, as early as possible, in order to avoid confusion. Some tests, such as activated partial thrombin time and ecarin clotting time, which have been reported as correlated with dabiga- tran concentrations, can be helpful for clinicians to determine the indication of IV tPA for such patients [4]. Conflicts of interest None. References 1. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M (2010) Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 8:790798 2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:11391151 3. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R (2010) Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 30:533534 4. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:527537 5. Matute MC, Guillán M, García-Caldentey J, Buisan J, Aparicio M, Masjuan J, Alonso de Leciñana M (2011) Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 106:178179 6. Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK, Silver FL, Investigators of the Registry of the Canadian Stroke Network (2011) Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke 42:10411045 S. Takeuchi (*) : K. Wada : K. Nagatani : N. Otani : H. Osada : H. Nawashiro Department of Neurosurgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan e-mail: [email protected] Acta Neurochir (2012) 154:87 DOI 10.1007/s00701-011-1196-x

Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients

Embed Size (px)

Citation preview

LETTER TO THE EDITOR

Intravenous tissue plasminogen activator treatmentfor ischemic stroke in dabigatran-treated patients

Satoru Takeuchi & Kojiro Wada & Kimihiro Nagatani &Naoki Otani & Hideo Osada & Hiroshi Nawashiro

Received: 12 August 2011 /Accepted: 27 September 2011 /Published online: 25 October 2011# Springer-Verlag 2011

Vergouwen et al. reported that intravenous tissue plasmin-ogen activator (IV tPA) treatment was not associated withan increased risk of secondary intracerebral hemorrhage orgastrointestinal hemorrhage in patients with acute ischemicstroke taking warfarin with an international normalizedratio (INR) <1.7 [6]. These results mean that IV tPAtreatment should not be discouraged in patients takingwarfarin with INR <1.7.

Recently, dabigatran, a new oral anticoagulant, wasapproved by the FDA. In the Randomized Evaluation ofLong-Term Anticoagulant Therapy trial, dabigatran wasshown to be as effective as warfarin in prevention of systemicembolism and future stroke, with lower risk of majorhemorrhage [2]. Additionally, dabigatran does not needmonitoring (differently from warfarin). Therefore, the numberof dabigatran-treated patients presenting with ischemic strokemay increase in the future. However, there is no guidelinewhether dabigatran-treated patients presenting with ischemicstroke can be considered eligible for IV tPA treatment or not.Only two case reports demonstrated the safety of IV tPAtreatment for acute ischemic stroke in dabigatran-treatedpatient [3, 5]. On the other hand, Ammollo et al. reportedthat dabigatran enhanced the susceptibility of plasma clots totPA-induced lysis in in vitro study [1]. Based on Ammollo’sresults, we can hypothesize that dabigatran may also enhancethe bleeding risk caused by tPA.

Although we recognize the lack of data on IV tPAtreatment for acute ischemic stroke in dabigatran-treated

patients, we need provisional guidelines of the topic, asearly as possible, in order to avoid confusion. Some tests,such as activated partial thrombin time and ecarin clottingtime, which have been reported as correlated with dabiga-tran concentrations, can be helpful for clinicians todetermine the indication of IV tPA for such patients [4].

Conflicts of interest None.

References

1. Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M(2010) Dabigatran enhances clot susceptibility to fibrinolysis bymechanisms dependent on and independent of thrombin-activatablefibrinolysis inhibitor. Thromb Haemost 8:790–798

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J,Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S,Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, DienerHC, Joyner CD, Wallentin L, RE-LY Steering Committee andInvestigators (2009) Dabigatran versus warfarin in patients withatrial fibrillation. N Engl J Med 361:1139–1151

3. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R(2010) Intravenous thrombolysis with recombinant tissue plasminogenactivator in a stroke patient treated with dabigatran. Cerebrovasc Dis30:533–534

4. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI,Stangier J (2006) Effects of the direct thrombin inhibitor dabigatranon ex vivo coagulation time in orthopaedic surgery patients: apopulation model analysis. Br J Clin Pharmacol 62:527–537

5. Matute MC, Guillán M, García-Caldentey J, Buisan J, Aparicio M,Masjuan J, Alonso de Leciñana M (2011) Thrombolysis treatmentfor acute ischaemic stroke in a patient on treatment with dabigatran.Thromb Haemost 106:178–179

6. Vergouwen MD, Casaubon LK, Swartz RH, Fang J, StamplecoskiM, Kapral MK, Silver FL, Investigators of the Registry of theCanadian Stroke Network (2011) Subtherapeutic warfarin is notassociated with increased hemorrhage rates in ischemic strokestreated with tissue plasminogen activator. Stroke 42:1041–1045

S. Takeuchi (*) :K. Wada :K. Nagatani :N. Otani :H. Osada :H. NawashiroDepartment of Neurosurgery, National Defense Medical College,3-2 Namiki,Tokorozawa, Saitama 359-8513, Japane-mail: [email protected]

Acta Neurochir (2012) 154:87DOI 10.1007/s00701-011-1196-x